Panalgo

What Panalgo does

Panalgo provides a cloud-based healthcare analytics platform built on Amazon Web Services, anchored by its flagship Instant Health Data (IHD) platform that enables life sciences organizations to generate real-world evidence from claims, electronic medical records, laboratory, and registry datasets without complex programming. The platform is augmented by specialized modules including IHD Cloud (cloud-native deployment), IHD Data Science Module (machine learning and predictive modeling), Model Studio (custom analytical model building), Ella AI (generative AI assistant for natural-language cohort creation), LinQ Notes (NLP search across unstructured clinical data), LinQ Cohort, and Patient Access Analytics (combined with MMIT market access data). Underpinning the platform is NorstellaLinQ, a proprietary real-world data asset with 74+ billion linked, tokenized data points spanning structured and unstructured EMR, laboratory, claims, and social determinants of health. The company serves pharmaceutical manufacturers, biotech firms, research organizations, commercial and market access teams, HEOR/RWE teams, medical affairs, and pharmacovigilance groups; the European Medicines Agency is a named customer. Panalgo sells primarily through enterprise SaaS subscriptions with quote-based annual pricing, supplemented by expert Evidence Generation Services and Training & Support. The company is headquartered in Boston with a European office in Amsterdam, and has operated as a brand within the Norstella conglomerate (formed May 2022 from the combination of Evaluate, MMIT, Panalgo, and The Dedham Group) following its acquisition by MMIT in September 2021.

Name

Panalgo

Legal name

Caerus US 1, Inc.

Website

https://panalgo.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

51–100 employees

Short description

Panalgo provides a cloud-based healthcare analytics platform (Instant Health Data) that lets life sciences organizations generate real-world evidence from claims, EHR, lab, and registry data without complex programming, serving pharmaceutical manufacturers, biotechs, research organizations, and regulators.

Ownership category

akta.pro rank

Product category

Healthcare Analytics Software

NAICS

Software Publishers (5132), Software Publishers (513210), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182)

SIC

Services-Prepackaged Software (7372), Services-Computer Programming, Data Processing, Etc. (7370)

akta.pro primary industry

Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)

akta.pro secondary industries

De-identification, Tokenization & Privacy-Preserving Data Platforms (HLACAIAK), Healthcare Outcomes & Real-World Evidence (RWE) Analytics (BPAHALAN), Data, Analytics & AI Consulting (BPAHAEAF), Data Monetization & Data Products Services (BPAEAHAL)

Keywords

• Healthcare data analytics
• Real-world evidence platform
• Clinical data analytics
• Health economics research
• Life sciences analytics

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. SaaS Platform Subscription: Software-as-a-service subscription model providing access to the IHD analytics platform. Pricing based on enterprise agreements with unlimited user access options available.
2. Analytics and Evidence Generation Services: Expert consulting services for evidence generation, HEOR studies, and custom analytics engagements alongside software deployment.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Panalgo develops and sells the Instant Health Data (IHD) analytics platform, a cloud-based software solution that allows life sciences organizations to analyze healthcare data without complex programming. The platform ingests claims, electronic medical records, laboratory, registry, and integrated real-world data sources, and is augmented by AI-powered tools (Ella AI, LinQ Notes), cloud deployment (IHD Cloud), and an integrated real-world data asset (NorstellaLinQ). Revenue is generated primarily through enterprise SaaS subscriptions and complementary evidence generation and analytics services.

Product overview

Panalgo offers a platform-plus-modules architecture centered on the Instant Health Data (IHD) analytics platform. IHD serves as the core powerhouse for real-world evidence generation, supporting rapid analysis of claims, EHR, lab, registry, and integrated datasets. The platform is augmented by specialized modules including IHD Cloud (cloud-native AWS deployment), IHD Data Science Module (machine learning/predictive analytics), Model Studio (custom model building), Ella AI (generative AI assistant for natural language cohort creation), LinQ Notes (unstructured data exploration), LinQ Cohort (cohort definition), and Patient Access Analytics (market access insights). The NorstellaLinQ Real-World Data asset—74+ billion linked data points—underpins these capabilities. The ecosystem is completed by expert Evidence Generation Services and a Partner Network. This integrated approach enables HEOR, epidemiology, regulatory, and commercial teams to generate insights without complex programming.

Differentiator

Problem solved

Functional benefit

Products and services

• Instant Health Data (IHD) Analytics Platform Flagship cloud-based healthcare analytics platform that eliminates complex programming, enabling life sciences teams to generate real-world evidence from claims, EHR, lab, and registry data in minutes rather than weeks.
• IHD Cloud Cloud-native deployment of the IHD platform within the client's AWS environment, featuring orchestration layer for optimized resource allocation, fault-tolerant architecture, advanced telemetry, and unlimited enterprise-wide user access.
• Model Studio Tool for building and deploying custom analytical models on the IHD platform.
• Ella AI Generative AI-powered assistant enabling life sciences teams to build research-ready cohorts, generate insights, and make decisions using natural language queries without SQL or coding, built on the NorstellaLinQ data asset.
• LinQ Notes Exploratory data tool enabling natural language search across unstructured clinical data including physician notes, imaging reports, dictations, and discharge summaries, requiring no NLP experience.
• LinQ Cohort Module for patient cohort definition and analysis within the IHD platform ecosystem.
• NorstellaLinQ Real-World Data Biopharma's first fully integrated data asset with over 74 billion linked, tokenized data points spanning structured EMR, laboratory, claims, and social determinants of health data; powers products and solutions across Norstella brands.
• Patient Access Analytics Solution combining the IHD platform with MMIT market access data for instant analysis of patient access barriers, coverage decisions, and prescribing patterns.
• Evidence Generation Services Expert analytics and evidence generation consulting services supporting HEOR, epidemiology, regulatory, and commercial teams in generating real-world evidence and custom analytics engagements alongside software deployment.
• Training & Support Training and support services for IHD platform users to enable adoption and effective use of the analytics platform.

Quantifiable outcome

• Complex analyses that would take weeks or months can be completed in days or hours
• +3 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature7 records

Partnerships

Nine partnerships are on record, tiered strategic and core.

• NavidencestrategicTechnology or Integration · 29 April 2025Strategic partnership embeds Navidence's validated patient phenotype definitions directly into Panalgo's workflow for faster insights and more accurate patient identification.
• Atropos Evidence NetworkstrategicTechnology or Integration · 4 February 2025NorstellaLinQ dataset achieved top decile scores on Atropos Real World Fitness Score and added to Atropos Evidence Network for data quality recognition.
• NorstellaLinQcoreTechnology or Integration · 8 October 2024NorstellaLinQ is the biopharma industry's first fully integrated data asset built on 74+ billion linked data points. Powers Panalgo's AI tools including Ella AI and provides unified data access across all Norstella brands.
• COTAstrategicTechnology or Integration · 11 September 2024Partnership adds oncology data from COTA to Panalgo's IHD platform, enhancing real-world data capabilities for cancer research and treatment analysis.
• Amazon Web Services (AWS)coreTechnology or Integration · 5 September 2024AWS powers IHD Cloud deployment, providing scalable and flexible cloud infrastructure. AWS re:Invent participation planned for 2024. Platform available in AWS Marketplace for seamless enterprise procurement.
• NorstellacoreStrategic or Co-development Partner · 3 May 2022Norstella is the parent company formed by combining Evaluate, MMIT, Panalgo, and The Dedham Group. Panalgo operates as a brand within the Norstella family united around the mission of helping patients gain access to life-saving therapies. Norstella provides Panalgo access to combined brand assets, cross-selling opportunities, and shared innovation infrastructure.
• MMITcoreChannel Partner/ Reseller/ Distributor · 28 September 2021MMIT acquired Panalgo in September 2021, leading to combined Patient Access Analytics solution leveraging both MMIT's market access data and Panalgo's IHD platform.
• Premier Inc.strategicTechnology or Integration · 21 May 2020Partnership made Premier Healthcare Database available through IHD platform, enabling researchers to access gold-standard hospital data without custom programming. Premier Applied Sciences division collaborated on integration.
• Atropos HealthstrategicStrategic or Co-development PartnerPartner Network member providing access to additional real-world evidence capabilities and data sources within the Norstella ecosystem.

Scale indicators6 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Veradigm (formerly Allscripts): Veradigm operates one of the largest ambulatory EHR-derived real-world data assets (Veradigm Network) used for life sciences research, clinical trials, and RWE. It competes with Panalgo by offering vertically integrated EHR data plus analytics for pharma.
• Atropos Health: Atropos Health operates a real-world evidence generation platform backed by an Evidence Network that scores data fitness for specific research questions. It is a Panalgo/Norstella Partner Network member while also being a peer for rapid RWE generation against de-identified patient data.
• TriNetX: TriNetX operates a global real-world data and analytics network for clinical research, enabling cohort feasibility, protocol design, and RWE generation for pharma sponsors. It competes head-on with IHD in serving biopharma RWE teams and is also a Partner Network ally of Panalgo's parent Norstella.
• Datavant: Datavant provides healthcare data connectivity, de-identification, and tokenization technology that links disparate patient datasets for life sciences RWE. Its data-linking layer is complementary to and competitive with NorstellaLinQ's 74B+ linked, tokenized data points.
• Flatiron Health: Flatiron Health provides real-world oncology data and evidence generation used by life sciences companies and academic researchers, now part of Roche. It competes directly with Panalgo's oncology RWE capabilities, particularly via the COTA partnership.
• Aetion: Aetion provides a science-driven RWE analytics platform used by biopharma, payers, and regulators (including FDA collaborations) for regulatory-grade real-world evidence generation. It directly competes with IHD on regulatory-grade HEOR and safety/efficacy analytics.
• ConcertAI: ConcertAI is an oncology-focused real-world data and AI analytics platform serving biopharma with patient-level EHR-derived data, evidence generation, and clinical trial solutions. It directly competes with Panalgo's IHD and NorstellaLinQ for oncology RWE workloads (and has hired talent from the same talent pool).

Broad incumbents

• IQVIA: IQVIA is the largest life sciences technology and analytics provider, operating a broad real-world evidence and clinical analytics platform that directly overlaps with Panalgo's IHD capabilities for HEOR, RWE, and commercial analytics. It is the most comprehensive incumbent competing for the same pharma wallet.
• Veeva Systems: Veeva provides the dominant life sciences CRM, regulatory, and clinical data cloud used by most top-20 pharma. While not a direct RWE analytics competitor, it is a broad incumbent sitting in the same buyer accounts and increasingly expanding into data and analytics adjacencies.
• Palantir Technologies: Palantir Foundry is increasingly adopted by large pharma for clinical, commercial, and RWE data integration and AI analytics. It represents a broad incumbent threat that can absorb mid-tier RWE analytics workloads with deeper enterprise platform economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/panalgo
• Xx.com/panalgoinsights

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Panalgo